Article Details

Celldex Therapeutics (NASDAQ:CLDX) Rating Increased to Hold at Zacks Investment Research

Retrieved on: 2021-07-08 00:11:15

Tags for this article:

Click the tags to see associated articles and topics

Celldex Therapeutics (NASDAQ:CLDX) Rating Increased to Hold at Zacks Investment Research. View article details on hiswai:

Excerpt

Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up